Tarsus Pharmaceuticals (TARS) News Today $47.36 -2.94 (-5.84%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$46.38 -0.98 (-2.08%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt PaydownMay 5 at 6:27 AM | prnewswire.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Here's What HappenedTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Should You Sell?May 5 at 3:33 AM | marketbeat.comAnalysts Just Made A Substantial Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) ForecastsMay 4 at 12:10 PM | finance.yahoo.comAllostery Investments LP Invests $753,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Allostery Investments LP purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 13,600 shares of the company's stock, valued aMay 4 at 7:45 AM | marketbeat.comAlly Bridge Group NY LLC Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Ally Bridge Group NY LLC cut its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 46.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 173,144 shares of the company's stock after sellingMay 4 at 7:45 AM | marketbeat.comVoleon Capital Management LP Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Voleon Capital Management LP purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 5,266 shares of the company's stock, valued at approximately $2May 4 at 5:28 AM | marketbeat.comEarnings call transcript: Tarsus Pharmaceuticals Q1 2025 sees robust sales growthMay 3 at 9:08 PM | investing.comTarsus Pharmaceuticals Reports 217% Increase in XDEMVY® Sales and Strengthens Financial Position with $135 Million Equity OfferingMay 3 at 9:08 PM | nasdaq.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 92.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 460,773May 3 at 4:28 AM | marketbeat.comTarsus Pharmaceuticals’ Earnings Call Highlights Robust GrowthMay 2 at 9:48 PM | tipranks.comTarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaignMay 2 at 10:55 AM | msn.comTarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comTarsus Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 1, 2025 | seekingalpha.comTarsus Reports First Quarter 2025 Financial Results and Recent Business AchievementsMay 1, 2025 | globenewswire.comAnalysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Target Price at $63.67May 1, 2025 | americanbankingnews.com20,811 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Artia Global Partners LPArtia Global Partners LP acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,811 shares of the comApril 29, 2025 | marketbeat.comBarclays PLC Lowers Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Barclays PLC lowered its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 24.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,664 shares of the company's stock afterApril 29, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Buy" by BrokeragesShares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have been assigned an average rating of "Buy" from the seven brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recomApril 29, 2025 | marketbeat.comBoothbay Fund Management LLC Reduces Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Boothbay Fund Management LLC lowered its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 43.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 156,403 shares of the company's stock after selling 119,160 shares during the periodApril 28, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Buys 397,190 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Gilder Gagnon Howe & Co. LLC boosted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5,636.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 404,237 shares of the company's stock after bApril 28, 2025 | marketbeat.comLord Abbett & CO. LLC Increases Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Lord Abbett & CO. LLC lifted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 115.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,279,987 shares of the company's stock after buying an additional 685,111April 28, 2025 | marketbeat.comLPL Financial LLC Sells 5,125 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)LPL Financial LLC lessened its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 44.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,468 shares of the company's stock after selling 5,125 shares dApril 28, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Wells Fargo & Company MNWells Fargo & Company MN boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 44.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,004 shares of the company's stApril 26, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Canada Pension Plan Investment BoardCanada Pension Plan Investment Board lifted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 13,616.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 82,300 shares of the company's stApril 25, 2025 | marketbeat.comTarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025April 24, 2025 | globenewswire.comSilverarc Capital Management LLC Grows Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Silverarc Capital Management LLC lifted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 64.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,955April 24, 2025 | marketbeat.comDiadema Partners LP Makes New $3.32 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Diadema Partners LP purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 60,000 shares of the company's stock, valued atApril 24, 2025 | marketbeat.comTarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meetingApril 24, 2025 | markets.businessinsider.comRock Springs Capital Management LP Invests $6.14 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Rock Springs Capital Management LP bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 110,889 shares of the company's stock, valued at approximately $6,14April 23, 2025 | marketbeat.comTarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual MeetingApril 22, 2025 | globenewswire.comAlpha DNA Investment Management LLC Purchases New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Alpha DNA Investment Management LLC acquired a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 7,818 shares of the company's stocApril 21, 2025 | marketbeat.comXTX Topco Ltd Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)XTX Topco Ltd bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 11,375 shares of the company's stock, valued at approximately $630,0April 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. lowered its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 70.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 129,184 shares of the company's stock after selling 310,983 shares during the quaApril 19, 2025 | marketbeat.comEAM Investors LLC Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)EAM Investors LLC acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 71,815 shares of the company's stock, valued at approximately $3,976,000. EAM Investors LLC owneApril 18, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Raised by Invesco Ltd.Invesco Ltd. raised its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 36.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 932,115 shares of the company's stock after purchasing an addApril 18, 2025 | marketbeat.com77,714 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Federated Hermes Inc.Federated Hermes Inc. acquired a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 77,714 shares of the company's stock, valued at approximatApril 15, 2025 | marketbeat.comAdvisory Services Network LLC Purchases 22,648 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Advisory Services Network LLC boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 59.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,459 sharApril 13, 2025 | marketbeat.comWellington Management Group LLP Has $7.57 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Wellington Management Group LLP reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 136,795 shares of the company's stock after selling 8,552 shares during the quartApril 13, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 7.2% - Should You Sell?Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 7.2% - Should You Sell?April 11, 2025 | marketbeat.comCapula Management Ltd Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Capula Management Ltd purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 6,396 shares of the company's stoApril 10, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,115,162 shares ofApril 10, 2025 | marketbeat.comDianne WhitfieldApril 10, 2025 | latimes.comAtika Capital Management LLC Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Atika Capital Management LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 177,200 shares of the company's stock, valueApril 8, 2025 | marketbeat.comKLP Kapitalforvaltning AS Invests $299,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)KLP Kapitalforvaltning AS bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 5,400 shares of the company's stock, valued at approximately $299,000. OtherApril 8, 2025 | marketbeat.comSei Investments Co. Purchases 12,689 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Sei Investments Co. grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 35.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 48,180 shares of the company's stock after acquiring an additional 12,689 shares during thApril 6, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $1.11 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Raymond James Financial Inc. acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,999 shares of the company's stock, valued at approximaApril 5, 2025 | marketbeat.comBlair William & Co. IL Makes New $1.51 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Blair William & Co. IL acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 27,230 shares of the company's stock, valued at approximately $1,508,000. BlaApril 4, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Buy" by BrokeragesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been given an average recommendation of "Buy" by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one hasApril 4, 2025 | marketbeat.comAIGH Capital Management LLC Grows Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)AIGH Capital Management LLC increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 224,713 shares of the company's stockMarch 31, 2025 | marketbeat.comPrudential Financial Inc. Boosts Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Prudential Financial Inc. lifted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 43.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 148,735 shares of the company's stock after buying an aMarch 31, 2025 | marketbeat.com Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address TARS Media Mentions By Week TARS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼1.170.73▲Average Medical News Sentiment TARS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼225▲TARS Articles Average Week Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lantheus News BridgeBio Pharma News TG Therapeutics News Legend Biotech News Sarepta Therapeutics News Telix Pharmaceuticals Limited American Depositary Shares News ADMA Biologics News Blueprint Medicines News Verona Pharma News Nuvalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARS) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARS Stock Free TARS Stock Alerts